Issue 4/2012

  • Can bioeconomy save the planet?

    In this issue:

    • Swiss Biotech Report reveals more investment in sector
    • Danes kick-off psychiatric genomics research hub
    • Wellcome Trust to aid UK biotech with £200m in funding
    • Analytica 2012 in Munich: Update on bioanalytics
    • Janus to commercialise inclusion body drug delivery system
    • Mabion announces IPO on Warsaw Stock Exchange
    • Intratumour heterogeneity challenges biomarker approach

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/4/pos/1.html?sort=asc&cHash=2aa63e7a3c47f54d547eeaaa494e591b

Kurszettel

Alle Kurse

TOP

  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%
  • ADDEX4.00 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.23 EUR0.00%
  • ACTELION108.80 CHF0.00%

TOP

  • SANTHERA82.95 CHF20.4%
  • LONZA101.10 CHF6.1%
  • MAGFORCE6.50 EUR5.7%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.10 EUR-24.5%
  • VITA 343.96 EUR-18.4%

TOP

  • SANTHERA82.95 CHF3758.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR195.2%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-68.1%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 22.08.2014